Granted Patent B2

US 12,275,959 · App. 17/556,847 · Granted Apr 15, 2025

Inventors: Thomas W. Chalberg, Jr. (Redwood City, CA); Jay Neitz (Seattle, WA); Maureen Neitz (Seattle, WA)

Assignee: Adverum Biotechnologies, Inc.

C12N7/00A61K35/761C12N15/86A61K38/00A61K48/00C12N2750/14143C12N2800/24C12N2830/008C12N2830/30C12N2830/42

Abstract

Claims (28)

1. A polynucleotide cassette for enhanced expression of a transgene in cone cells of a mammalian retina, comprising:

(a) a promoter region consisting of a truncated opsin promoter having a sequence selected from the group consisting of (i) 95% or more sequence identity to SEQ ID NO: 55 or functional fragment thereof comprising SEQ ID NO:80, (ii) SEQ ID NO: 82, and (iii) SEQ ID NO: 83;

(b) a coding sequence operatively linked to the promoter region; and

(c) a polyadenylation site operatively linked to the coding sequence.

2. The polynucleotide cassette of claim 1 , further comprising a 5′ untranslated region (5′UTR) consisting essentially of a sequence having a sequence identity of 95% or more to a sequence selected from the group consisting of SEQ ID NO: 56, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO: 84, SEQ ID NO: 85, SEQ ID NO: 86, SEQ ID NO: 87, SEQ ID NO:88, and SEQ ID NO:89.

3. The polynucleotide cassette of claim 2 , wherein the 5′ UTR does not comprise a polynucleotide ATG.

4. The polynucleotide cassette of claim 2 , wherein the 5′ UTR consists essentially of a sequence having a sequence identity of 95% or more to the full length of SEQ ID NO:85 or SEQ ID NO:86.

5. The polynucleotide cassette of claim 2 , further comprising an intron.

6. The polynucleotide cassette of claim 5 , wherein the intron comprises a sequence having a sequence identity of 95% or more to a sequence selected from the group consisting of SEQ ID NO:5, SEQ ID NO:59, and SEQ ID NO:60.

7. The polynucleotide cassette of claim 6 , wherein the intron is located within the polynucleotide sequence comprising the 5′ UTR.

8. The polynucleotide cassette of claim 1 , further comprising a translation initiation sequence.

9. The polynucleotide cassette of claim 8 , wherein the translation initiation sequence comprises a polynucleotide sequence consisting essentially of SEQ ID NO:72 or SEQ ID NO:73.

10. The polynucleotide cassette of claim 1 , further comprising an enhancer sequence having a sequence identity of 95% or more to SEQ ID NO:52 or a functional fragment thereof.

11. The polynucleotide cassette of claim 10 , wherein the enhancer sequence consists essentially of a sequence having a sequence identity of 95% or more to the full length of SEQ ID NO:51.

12. The polynucleotide cassette of claim 1 , wherein expression of the coding sequence is greater than expression of the coding sequence when the promoter region is replaced with the promoter region of SEQ ID NO: 1 when introduced into a mammalian cone cell.

13. A recombinant adeno-associated virus (rAAV) comprising:

(a) an AAV capsid protein, and

(b) the polynucleotide cassette of claim 1 flanked by AAV ITRs.

14. A pharmaceutical composition comprising an rAAV comprising (a) an AAV capsid protein and (b) a polynucleotide cassette for enhanced expression of a transgene in cone cells of a mammalian retina, comprising:

(a) a promoter region consisting of a truncated opsin promoter having a sequence selected from the group consisting of (i) 95% or more sequence identity to SEQ ID NO: 55 or functional fragment thereof comprising SEQ ID NO:80, (ii) SEQ ID NO: 82, and (iii) SEQ ID NO: 83;

(b) a coding sequence operatively linked to the promoter region; and

(c) a polyadenylation site operatively linked to the coding sequence; wherein the polynucleotide cassette is flanked by AAV ITRs and a pharmaceutical excipient.

15. A method for expressing a transgene in cone cells, comprising:

contacting one or more cone cells with an effective amount of a recombinant adeno-associated virus comprising (a) an AAV capsid protein and (b) a polynucleotide cassette for enhanced expression of a transgene in cone cells of a mammalian retina, comprising:

(a) a promoter region consisting of a truncated opsin promoter having a sequence selected from the group consisting of (i) 95% or more sequence identity to SEQ ID NO: 55 or functional fragment thereof comprising SEQ ID NO:80, (ii) SEQ ID NO: 82, and (iii) SEQ ID NO: 83;

(b) a coding sequence operatively linked to the promoter region; and

(c) a polyadenylation site operatively linked to the coding sequence; wherein the polynucleotide cassette is flanked by AAV ITRs, wherein the transgene is expressed at detectable levels in the one or more cone cells.

16. The method according to claim 15 , comprising detecting the expression in the cone cells, wherein expression is detected in 60% or more of the cone cells.

Assignments (4)

Continuity (5)

References Cited (400)